MX375500B - Anticuerpos anti-factor del complemento c1q y uso de los mismos. - Google Patents

Anticuerpos anti-factor del complemento c1q y uso de los mismos.

Info

Publication number
MX375500B
MX375500B MX2015017341A MX2015017341A MX375500B MX 375500 B MX375500 B MX 375500B MX 2015017341 A MX2015017341 A MX 2015017341A MX 2015017341 A MX2015017341 A MX 2015017341A MX 375500 B MX375500 B MX 375500B
Authority
MX
Mexico
Prior art keywords
antibodies
complement factor
complement
factor
methods
Prior art date
Application number
MX2015017341A
Other languages
English (en)
Other versions
MX2015017341A (es
Inventor
Arnon Rosenthal
Michael Leviten
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of MX2015017341A publication Critical patent/MX2015017341A/es
Publication of MX375500B publication Critical patent/MX375500B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)

Abstract

La presente invención proporciona anticuerpos antiC1Q y métodos de uso de los mismos.
MX2015017341A 2013-07-09 2014-07-09 Anticuerpos anti-factor del complemento c1q y uso de los mismos. MX375500B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844369P 2013-07-09 2013-07-09
US201361871813P 2013-08-29 2013-08-29
PCT/US2014/046042 WO2015006504A1 (en) 2013-07-09 2014-07-09 Anti-complement factor c1q antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2015017341A MX2015017341A (es) 2016-07-06
MX375500B true MX375500B (es) 2025-03-06

Family

ID=52280583

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015017341A MX375500B (es) 2013-07-09 2014-07-09 Anticuerpos anti-factor del complemento c1q y uso de los mismos.
MX2020010141A MX2020010141A (es) 2013-07-09 2015-12-15 Anticuerpos anti-factor del complemento c1q y uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010141A MX2020010141A (es) 2013-07-09 2015-12-15 Anticuerpos anti-factor del complemento c1q y uso de los mismos.

Country Status (23)

Country Link
US (7) US20160159890A1 (es)
EP (3) EP3019523A4 (es)
JP (2) JP6462680B2 (es)
KR (1) KR102321320B1 (es)
CN (1) CN105682740B (es)
AU (1) AU2014287221C1 (es)
BR (1) BR112016000106B1 (es)
CA (1) CA2916521C (es)
DK (1) DK3019240T3 (es)
EA (1) EA037325B1 (es)
ES (1) ES2978917T3 (es)
FI (1) FI3019240T3 (es)
HU (1) HUE066722T2 (es)
IL (1) IL243506B (es)
MX (2) MX375500B (es)
MY (1) MY175896A (es)
NZ (1) NZ715455A (es)
PL (1) PL3019240T3 (es)
PT (1) PT3019240T (es)
SG (3) SG11201510316UA (es)
SI (1) SI3019240T1 (es)
WO (2) WO2015006504A1 (es)
ZA (1) ZA201600157B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US8148330B2 (en) 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
US20160090425A1 (en) * 2013-05-15 2016-03-31 Annexon, Inc. Anti-complement factor c1s antibodies and uses thereof
BR112016000106B1 (pt) 2013-07-09 2023-11-21 Annexon, Inc. Anticorpos anti-c1q e usos dos mesmos, célula de hibridoma, composição farmacêutica e métodos de detecção de sinapses em uma amostra biológica referências cruzadas a pedidos relacionados
WO2016073685A1 (en) * 2014-11-05 2016-05-12 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
HUE057432T2 (hu) * 2015-04-07 2022-05-28 Alector Llc Anti-sortilin antitestek és ezek alkalmazási módjai
EP3380518B1 (en) * 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
EP3454901A4 (en) * 2016-05-09 2020-07-29 Annexon, Inc. COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE SPINAL AMYOTROPHY
CA3030872A1 (en) * 2016-07-19 2018-01-25 Annexon, Inc. Compositions and methods for treating frontotemporal dementia
WO2018050878A1 (en) 2016-09-19 2018-03-22 F. Hoffmann-La Roche Ag Complement factor based affinity chromatography
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
CN106699883B (zh) * 2016-12-19 2020-08-07 中国兽医药品监察所 豚鼠补体C1q-B单克隆抗体60G4的制备与应用
CN106822863A (zh) * 2017-01-04 2017-06-13 国家纳米科学中心 多肽‑抗体免疫偶联物及其制备方法
CN109843927B (zh) * 2017-03-06 2022-06-21 江苏恒瑞医药股份有限公司 抗b7-h3抗体、其抗原结合片段及其医药用途
CN116376973A (zh) * 2017-09-29 2023-07-04 瑞泽恩制药公司 经基因修饰的啮齿动物基因组
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
EP3737472A1 (en) * 2018-01-09 2020-11-18 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie Modulators of c1q, in particular of the interaction of apoe with c1q, and uses of the modulators in the therapy of neuronal diseases and inflammation
EP3801772A1 (en) 2018-06-11 2021-04-14 Aarhus Universitet Single domain antibodies for complement regulation
RS64034B1 (sr) 2018-07-13 2023-04-28 Alector Llc Anti-sortilin antitela i načini njihove upotrebe
CN112805299B (zh) 2018-10-05 2025-09-16 西雅图儿童医院以西雅图儿童研究机构名义经营 针对原发性免疫缺陷、胱氨酸病和威尔逊病的新生儿筛查
CA3118453A1 (en) * 2018-11-02 2020-05-07 The Regents Of The University Of California Compositions and methods for treating brain injury
BR112021021689A2 (pt) 2019-05-15 2022-03-22 Chugai Pharmaceutical Co Ltd Molécula de ligação a antígeno, composição farmacêutica, e método
KR20220082698A (ko) * 2019-10-16 2022-06-17 추가이 세이야쿠 가부시키가이샤 항체, 약학 조성물, 및 방법
MX2022004287A (es) * 2019-10-17 2022-07-19 Annexon Inc Composiciones y métodos para tratar trastornos sanguineos.
US11940448B2 (en) 2020-03-31 2024-03-26 Seattle Children's Hospital Proteomic screening for lysosomal storage diseases
US12523662B2 (en) 2020-04-02 2026-01-13 Seattle Children's Hospital Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia
EP4146276A4 (en) * 2020-05-05 2024-08-14 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Compositions and methods for treating epilepsy
WO2021226513A1 (en) 2020-05-08 2021-11-11 President And Fellows Of Harvard College Methods for treating inflammatory and autoimmune disorders
WO2021250323A1 (en) * 2020-06-09 2021-12-16 Helsingin Yliopisto Anti-cox-2 autoantibody as a diagnostic marker, and methods, kits and uses related thereto
EP4185592A4 (en) 2020-07-20 2024-08-21 Annexon, Inc. COMPLEMENT FACTOR INHIBITORS AND THEIR USES
JP2023545501A (ja) * 2020-10-16 2023-10-30 アネクソン，インコーポレーテッド 血液障害を処置するための組成物及び方法
US20240059765A1 (en) * 2020-12-04 2024-02-22 Annexon, Inc. Compositions and methods for treating ocular diseases
GB202113673D0 (en) * 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
CA3235802A1 (en) * 2021-10-21 2023-04-27 Stefano BIRESSI Compositions and methods for treating muscular dystrophy
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
GB2629959A (en) * 2021-12-29 2024-11-13 Curateq Biologics Private Ltd C1Q binding assay
US20250074973A1 (en) * 2021-12-30 2025-03-06 Annexon, Inc. Compositions and methods for treating huntington’s disease
KR20240135818A (ko) 2022-01-14 2024-09-12 애넥슨, 인코포레이티드 보체 인자의 저해제 및 이의 용도
JP2025533847A (ja) * 2022-10-07 2025-10-09 アネクソン，インコーポレーテッド 抗ｃ１ｑ抗体のための製剤
WO2024154122A1 (en) 2023-01-18 2024-07-25 Gilboa Therapeutics LTD Immune cells expressing a complement receptor and uses thereof
EP4670793A1 (en) * 2024-06-24 2025-12-31 Montis Biosciences BV C1Q ANTIGEN BINDING MOLECULES
CN119326377B (zh) * 2024-10-15 2025-07-22 复旦大学 一种基于影像的认知水平评估方法
CN120685919A (zh) * 2025-08-22 2025-09-23 中国科学院长春应用化学研究所 一种C1q补体蛋白在制备检测Aβ42蛋白的元件中的应用、一种检测Aβ42蛋白的芯片及其应用

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4595654A (en) 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
ES2058199T3 (es) 1987-09-23 1994-11-01 Bristol Myers Squibb Co Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US20020058311A1 (en) 1995-06-13 2002-05-16 Browne Michael Jospeh Chimeric leptin fused to immunoglobulin domain and use
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DK0941344T3 (da) * 1996-11-27 2004-09-27 Genentech Inc Humaniserede anti-CD11a-antistoffer
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE324443T1 (de) * 1997-08-26 2006-05-15 Zymogenetics Inc Für adipozyten spezifische protein homologe
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030170781A1 (en) * 1999-07-01 2003-09-11 Zymogenetics, Inc. Secreted protein zacrp4
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6781029B2 (en) 2000-07-13 2004-08-24 University Of South Florida Transgenic animal and methods
AU2002226074A1 (en) 2000-10-26 2002-05-06 Wisconsin Alumni Research Foundation. E. coli 0157:h7 c1 esterase inhibitor-binding protein stce and uses thereof
AU2002233340B2 (en) 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
AU2002365153A1 (en) * 2001-11-07 2003-06-30 Human Genome Sciences, Inc. 41 human secreted proteins
US20040248156A1 (en) * 2001-12-03 2004-12-09 Tianhua Hu Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides
US20050214786A1 (en) 2002-02-22 2005-09-29 Human Genome Sciences, Inc. 26 human secreted proteins
EP1556684A4 (en) 2002-11-01 2008-01-23 Univ Colorado Regents QUANTITATIVE ANALYSIS OF PROTEIN ISOFORMS USING FLIGHT TIME MASS SPECTROMETRY BY MATRIX ASSISTED LASER DESORPTION / IONIZATION
CN1787741B (zh) 2003-05-15 2011-08-17 唐纳士公司 用于预防和治疗败血症的方法与组合物
US20050019326A1 (en) * 2003-06-16 2005-01-27 The Brigham And Women's Hospital, Inc. C1q complement inhibitors and methods of use thereof
WO2005002512A2 (en) 2003-06-19 2005-01-13 University Of Rochester Immunotherapeutic vaccine strategy
US8501705B2 (en) * 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
CN101001872A (zh) 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
US7544855B2 (en) 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
AU2005313971B2 (en) 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
CN102764279B (zh) * 2005-10-14 2015-04-01 全面技术公司 改变细胞功能的方法和组合物
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US8148330B2 (en) * 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
PL2004688T5 (pl) * 2006-03-23 2014-09-30 Bioarctic Neuroscience Ab Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
US9388235B2 (en) 2006-09-05 2016-07-12 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
CN101657097A (zh) 2007-03-01 2010-02-24 先进视觉疗法公司 以炎症为特征的疾病的治疗
JP5933894B2 (ja) 2007-09-14 2016-06-15 アディマブ， エルエルシー 合理的に設計された、合成抗体ライブラリおよびその使用
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
UY31520A1 (es) 2007-12-11 2009-08-03 Proteinas de union a antigenos
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2010065425A1 (en) 2008-12-01 2010-06-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
EP2426916A4 (en) 2009-04-28 2017-09-06 Panasonic Corporation Receiver
KR102810907B1 (ko) 2010-07-16 2025-05-21 아디맵 엘엘씨 항체 라이브러리
WO2012067267A1 (en) 2010-11-18 2012-05-24 Takahiro Ochi TESTING METHOD USING ANTI-C1q MONOCLONAL ANTIBODY
SG194176A1 (en) 2011-05-27 2013-12-30 Glaxo Group Ltd Bcma (cd269/tnfrsf17) -binding proteins
US9127061B2 (en) 2011-06-24 2015-09-08 Perseus Proteomics Inc. Anti-human P-cadherin (CDH3) recombinant antibody
HRP20201004T1 (hr) 2011-12-20 2020-10-16 Medimmune, Llc Modificirani polipeptidi za skelete bispecifičnog protutijela
EP2847224A4 (en) 2012-05-10 2016-04-27 Zymeworks Inc SINGLE ARM MONOVALENT ANTIBODY CONSTRUCTS AND USES THEREOF
KR20200015952A (ko) 2012-06-18 2020-02-13 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
CN104870475B (zh) * 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
WO2014169076A1 (en) 2013-04-09 2014-10-16 Annexon,,Inc. Methods of treatment for neuromyelitis optica
US20160090425A1 (en) 2013-05-15 2016-03-31 Annexon, Inc. Anti-complement factor c1s antibodies and uses thereof
BR112016000106B1 (pt) 2013-07-09 2023-11-21 Annexon, Inc. Anticorpos anti-c1q e usos dos mesmos, célula de hibridoma, composição farmacêutica e métodos de detecção de sinapses em uma amostra biológica referências cruzadas a pedidos relacionados
WO2016073685A1 (en) 2014-11-05 2016-05-12 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
EP3380518B1 (en) 2015-11-24 2026-03-25 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
EP3454901A4 (en) 2016-05-09 2020-07-29 Annexon, Inc. COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE SPINAL AMYOTROPHY
CA3030872A1 (en) 2016-07-19 2018-01-25 Annexon, Inc. Compositions and methods for treating frontotemporal dementia
CA3118453A1 (en) 2018-11-02 2020-05-07 The Regents Of The University Of California Compositions and methods for treating brain injury
MX2022004287A (es) 2019-10-17 2022-07-19 Annexon Inc Composiciones y métodos para tratar trastornos sanguineos.
CN113185611A (zh) 2019-12-05 2021-07-30 启愈生物技术(上海)有限公司 含有肿瘤相关抗原taa抗体的三功能融合蛋白及其应用
EP4146276A4 (en) 2020-05-05 2024-08-14 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Compositions and methods for treating epilepsy
JP2023537553A (ja) 2020-08-14 2023-09-04 中外製薬株式会社 ワンアームド抗原結合分子およびその使用
JP2023545501A (ja) 2020-10-16 2023-10-30 アネクソン，インコーポレーテッド 血液障害を処置するための組成物及び方法
US20240059765A1 (en) 2020-12-04 2024-02-22 Annexon, Inc. Compositions and methods for treating ocular diseases
US12486322B2 (en) 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof

Also Published As

Publication number Publication date
EP4252769A3 (en) 2023-11-29
MY175896A (en) 2020-07-14
AU2014287221B2 (en) 2019-09-12
SG10202008809RA (en) 2020-10-29
ES2978917T3 (es) 2024-09-23
HUE066722T2 (hu) 2024-09-28
US10227398B2 (en) 2019-03-12
US20240083987A1 (en) 2024-03-14
US20190211084A1 (en) 2019-07-11
FI3019240T3 (fi) 2024-05-30
EP3019523A1 (en) 2016-05-18
EP3019240A1 (en) 2016-05-18
WO2015006504A1 (en) 2015-01-15
SI3019240T1 (sl) 2024-07-31
US10590190B2 (en) 2020-03-17
US12534522B2 (en) 2026-01-27
BR112016000106B1 (pt) 2023-11-21
US10927167B2 (en) 2021-02-23
CN105682740A (zh) 2016-06-15
JP6462680B2 (ja) 2019-01-30
WO2015006507A1 (en) 2015-01-15
JP2019071889A (ja) 2019-05-16
DK3019240T3 (da) 2024-06-03
BR112016000106A2 (pt) 2017-12-12
CN105682740B (zh) 2021-06-11
AU2014287221A1 (en) 2016-01-21
KR102321320B1 (ko) 2021-11-03
US9708394B2 (en) 2017-07-18
EA037325B1 (ru) 2021-03-12
AU2014287221C1 (en) 2020-03-05
PT3019240T (pt) 2024-06-06
US20160159890A1 (en) 2016-06-09
IL243506B (en) 2021-07-29
PL3019240T3 (pl) 2024-08-19
US11649279B2 (en) 2023-05-16
JP2016526393A (ja) 2016-09-05
KR20160058752A (ko) 2016-05-25
US20200239557A1 (en) 2020-07-30
NZ715455A (en) 2021-12-24
EP3019240A4 (en) 2017-01-04
SG10201710758PA (en) 2018-02-27
IL243506A0 (en) 2016-02-29
MX2020010141A (es) 2020-10-20
CA2916521A1 (en) 2015-01-15
EA201690182A1 (ru) 2016-10-31
US20170334976A1 (en) 2017-11-23
JP6653009B2 (ja) 2020-02-26
HK1225678A1 (zh) 2017-09-15
EP4252769A2 (en) 2023-10-04
US20210277096A1 (en) 2021-09-09
SG11201510316UA (en) 2016-01-28
EP3019523A4 (en) 2016-12-28
MX2015017341A (es) 2016-07-06
CA2916521C (en) 2023-03-07
EP3019240B1 (en) 2024-03-13
US20160368973A1 (en) 2016-12-22
ZA201600157B (en) 2025-10-29

Similar Documents

Publication Publication Date Title
MX375500B (es) Anticuerpos anti-factor del complemento c1q y uso de los mismos.
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
MX2016005631A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
BR112015032224A2 (pt) anticorpos anti-fcrh5
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
BR112017009297A2 (pt) anticorpos antifator de complemento c1q humanizados e usos dos mesmos
UY34540A (es) Heteroarilos y usos de los mismos
UY34797A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
MX372661B (es) Anticuerpos anti-htra1 y metodos de uso.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration